Peptides in Thailand are discussed across endocrinology, metabolic medicine, fitness and longevity, but the word peptide does not tell you whether a product is proven, approved or safe. This guide separates established medicines from experimental compounds, explains what the human research actually shows and gives readers a practical way to assess popular names such as BPC-157, ipamorelin, CJC-1295 and tesamorelin. It is educational content for informed conversations with qualified health professionals, not a treatment or purchasing guide.
What is a peptide?
A peptide is a chain of amino acids, usually shorter than a protein. Natural peptides act as hormones, neurotransmitters and local signals; insulin, glucagon-like peptide-1 and growth hormone-releasing hormone are familiar examples. Scientists can also manufacture peptide analogues that resist breakdown, bind a receptor differently or remain active longer.
That definition covers very different products. An approved medicine has a specified active ingredient, manufacturing controls, a tested formulation, an authorized indication and regulated labeling. A chemical sold as "research use only" has not passed that same product-level review. The EMA's 2026 synthetic-peptide guideline highlights why identity, impurities, stereoisomers, aggregation, sterilization and immunogenicity all matter. A label showing the expected amino-acid sequence is therefore not enough to establish clinical quality.
MK-677 illustrates another source of confusion. It is grouped with peptides in online discussions because it activates the ghrelin receptor and changes growth-hormone signaling, but it is an orally active non-peptide small molecule. Classification should follow chemistry and pharmacology, not marketing categories.
Approved medicine, investigational drug or research chemical?
Use three questions in order: What exactly is the molecule? What evidence exists in humans? Is the exact product approved for the proposed use?
| Compound | What it is | Best available human evidence | US regulatory position |
|---|---|---|---|
| Tesamorelin | GHRH analogue | Multiple randomized trials in adults with HIV-associated lipodystrophy | FDA approved for one narrow indication |
| Sermorelin | GHRH(1-29) analogue | Historical diagnostic and pediatric growth studies | Previously marketed as Geref; discontinued, not for safety or effectiveness reasons |
| CJC-1295 | Long-acting GHRH analogue, with ambiguous commercial naming | Short studies in healthy adults; no established treatment benefit | Not FDA approved |
| GHRP-2 and GHRP-6 | Synthetic ghrelin-receptor agonist peptides | Small human endocrine and appetite studies | Not FDA approved; FDA flags compounding safety concerns |
| Ipamorelin | Selective ghrelin-receptor agonist peptide | A negative phase 2 trial in postoperative ileus plus preclinical pharmacology | Not FDA approved |
| MK-677 | Non-peptide ghrelin mimetic | Randomized trials show hormonal and body-composition effects, but important safety and efficacy limits | Not FDA approved |
| BPC-157 | Synthetic 15-amino-acid peptide | Predominantly laboratory and animal research; very small, weak human studies | Not FDA approved |
| TB-500 | Usually described as a seven-amino-acid thymosin beta-4 fragment | Animal and cell work; no established human treatment evidence for TB-500 itself | Not FDA approved |
| Semax | ACTH-fragment-derived heptapeptide | Limited regional clinical literature and preclinical neuroscience research | Not FDA approved in the US |
Approval is indication-specific. The FDA label for tesamorelin does not validate CJC-1295, sermorelin or other growth-hormone secretagogues, and it does not turn tesamorelin into a general weight-loss drug. Likewise, research on full-length thymosin beta-4 eye drops cannot be treated as clinical proof for systemic TB-500.
How to read peptide research without being misled
Start with the study population
A change in a biomarker among healthy volunteers is not the same as symptom relief or better health outcomes in patients. CJC-1295 studies show that it can raise growth hormone and IGF-1, for example, but they do not establish that it treats growth-hormone deficiency, improves recovery or reverses aging. Look for trials in people who actually have the condition being discussed.
Separate surrogate outcomes from useful outcomes
Growth hormone, IGF-1, body water, fat-free mass and gene expression are surrogate measures. They help researchers understand biology, but they do not automatically predict strength, mobility, pain relief or fewer injuries. In a randomized MK-677 study, fat-free mass increased without a corresponding improvement in strength or function. That is a clinically important difference.
Check whether the studied substance matches the advertised one
Names such as "CJC-1295 without DAC" and "TB-500" are used inconsistently. Salt form, sequence, formulation and route can change exposure and risk. The FDA's current compounding safety-risk list repeatedly identifies peptide-related impurities, aggregation and active-ingredient characterization as unresolved concerns. Evidence about a well-characterized research material cannot simply be transferred to an unknown vial.
Put evidence in the right order
A useful hierarchy is:
- Current regulator-approved labeling for the exact product and indication.
- Replicated randomized controlled trials with clinically relevant outcomes.
- Smaller controlled human studies and registered trials.
- Uncontrolled case series and case reports.
- Animal, tissue and cell experiments.
- Testimonials, clinic claims and social-media posts.
Preclinical findings can justify more research. They cannot establish a human treatment, a safe route or a suitable dose.
Growth-hormone-related compounds are not interchangeable
This cluster contains two different upstream pathways. GHRH analogues such as sermorelin, CJC-1295 and tesamorelin activate GHRH receptors on pituitary somatotroph cells. Ghrelin-receptor agonists such as GHRP-2, GHRP-6, ipamorelin and MK-677 activate the growth hormone secretagogue receptor, or GHSR-1a. Both can increase growth-hormone signaling, but their duration, off-target hormonal effects, appetite effects and evidence bases differ.
Combining compounds is often promoted as "synergy," yet a stronger biomarker response does not prove a better clinical outcome. It can also make adverse effects and lab interpretation harder to attribute. Elevated IGF-1, fluid retention, altered glucose handling, headache, injection reactions and changes in appetite are not interchangeable minor details; their relevance depends on the person, compound and underlying condition.
Repair and neurocognitive claims need extra skepticism
BPC-157 and TB-500 are marketed around healing, while Semax is promoted for focus or neuroprotection. These claims commonly jump from a mechanism to a promised result. Rat tendon cells responding to BPC-157, a mouse wound closing after a thymosin fragment or altered neurotrophin gene expression after Semax does not establish that an unapproved product repairs a human tendon or improves cognition.
Ask whether the evidence includes a control group, validated outcomes, enough participants, transparent adverse-event reporting and independent replication. If those elements are missing, the correct conclusion is "uncertain," not "promising enough to self-experiment."
What readers in Thailand should verify
Thailand requires finished medicines to be registered before manufacture or import. The official Thai FDA drug search lets users check product records, while the agency's drug-approval guidance explains the registration requirement. Search the exact brand, active ingredient, manufacturer and registration number; do not assume that a clinic menu, marketplace listing or overseas approval confirms Thai authorization.
Before discussing any peptide-related intervention, bring a clinician:
- the exact product name and ingredient list;
- the claimed indication and the evidence supporting it;
- all medicines, supplements and performance products being used;
- relevant diagnoses, especially diabetes, cancer, pituitary disease or cardiovascular disease;
- the competition rules that apply if you are an athlete.
The 2026 WADA Prohibited List prohibits growth-hormone releasing factors, growth-hormone secretagogues and mimetics, and explicitly covers thymosin beta-4 and its derivatives such as TB-500. Athletes should verify every substance before use; a "research" label is not an anti-doping exemption.
Common peptide-research mistakes
- Treating sale as approval. Availability only proves that someone is offering a product.
- Calling every secretagogue a peptide. MK-677 is not one, despite its placement in peptide catalogs.
- Extrapolating from animals to treatment. Mechanistic evidence is a starting point, not a clinical endpoint.
- Ignoring formulation and identity. A peptide sequence can contain deletion products, aggregates or other impurities.
- Using a lab change as proof of benefit. Higher IGF-1 or lean mass can occur without better function.
- Borrowing approval across molecules. Tesamorelin's indication does not validate other GHRH analogues.
- Overlooking sports rules. WADA categories can apply even when a compound is not named on a sales page.
Questions to take to a qualified clinician
Use this checklist to turn vague marketing claims into a useful medical discussion:
- Is the proposed product registered for this exact indication in Thailand?
- What randomized human evidence supports the outcome I care about?
- Does the evidence use the same molecule, formulation and route?
- What established treatment addresses the underlying diagnosis?
- Which known and unknown risks matter with my conditions and medicines?
- How would benefit and harm be assessed with clinically meaningful endpoints?
If clear answers are unavailable, uncertainty is itself a decision-relevant finding.
Frequently asked questions
Are all peptides medicines?
No. Peptide describes a type of molecule, not a regulatory status. Some peptides are approved prescription medicines, while others are investigational compounds with little or no reliable human evidence.
Does a product being sold in Thailand mean it is Thai FDA approved?
No. Online availability, clinic advertising and product registration are different things. Check the exact product and manufacturer in the Thai FDA drug database and ask a licensed pharmacist or physician to confirm its status.
Which compound in this guide has a current FDA-approved medical use?
Tesamorelin has a specific US approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval does not extend to general weight loss, anti-aging or bodybuilding.
A safer next step
Choose the compound page that matches your question, note the difference between mechanism and proven outcome, and take the cited sources to a Thai-licensed physician or pharmacist. The goal is not to find a more persuasive claim; it is to identify the exact product, the actual evidence and the approved alternatives for the health problem involved.